Study of a new injectable drug for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This early-stage study tests a new injectable medicine (KT501) for people with moderate to severe rheumatoid arthritis who have not responded well enough to other treatments and have specific antibodies in their blood. It aims to see how safe and well-tolerated the drug is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have had rheumatoid arthritis for at least 6 months and it is moderate to severe.
- You have tested positive for rheumatoid factor or anti-CCP antibodies.
- You are not currently taking certain other medications for RA (like biologics or JAK inhibitors) without approval, or you are on a stable dose of traditional DMARDs.
- You do not have any other autoimmune disease, active infection, cancer in the last 5 years, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study testing a new injectable treatment called KT502 for people with moderate-to-severe rheumatoid arthritis (RA) that hasn't responded well to standard treatments. The study will check if the medication is safe and how the body responds to it.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
This trial tests a new medicine called VDJ001 for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. The goal is to see if VDJ001 helps reduce joint pain and swelling better than a placebo.
This trial tests a new medication called ADI-001 to see if it can help people with rheumatoid arthritis. It is for adults who meet the standard criteria for RA and are in generally good health otherwise.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't been controlled by multiple standard treatments. It aims to see if telitacicept can help reduce inflammation and improve symptoms.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.